Dibucaine (Cinchocaine)
- Atc Codes:C05AD04#D04AB02#N01BB06#S01HA06
- CAS Codes:85-79-0#61-12-1
- PHARMGKB ID:85-79-0#61-12-1
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Germany: Doloposterine; Greece: Nupercainal; Portugal: Nupercainal.
North America
Canada: Nupercainal.
Latin America
Brazil: Nupercainal.
Asia
Japan: Percamin.
Drug combinations
Dibucaine and Dexamethasone
Dibucaine and Diphenhydramine
Dibucaine and Fluocortolone
Dibucaine and Prednisolone
Dibucaine, Butane-1,3–diol, and Dexamethasone
Dibucaine, Esculoside, Hydrocortisone, and Neomycin
Chemistry
Dibucaine: C~20~H~29~N~3~O~2~. Mw: 343.46. (1) 4-Quinolinecarboxamide, 2-butoxy-N-[2-(diethylamino)ethyl]-; (2) 2-Butoxy-N-[2-(diethylamino)ethyl]cinchoninamide. CAS-85-79-0.
Dibucaine Hydrochloride: C~20~H~29~N~3~O~2~ HCl. Mw: 379.92. 4-Quinolinecarboxamide, 2-butoxy-N-[2-(diethylamino)ethyl]-, monohydrochloride. CAS-61-12-1.
Pharmacologic Category
Skin and Mucous Membrane Agents; Antipruritics and Local Anesthetics. (ATC-Code: C05AD04; D04AB02; N01BB06; S01HA06).
Mechanism of action
Local anesthetic with a long duration of action. Dibucaine binds selectively to the intracellular surface of sodium channels to block influx of sodium into the axon. As a result, depolarization is prevented.
Therapeutic use
Fast, temporary relief of pain and itching due to hemorrhoids, minor burns, other minor skin conditions.
Pregnancy and lactiation implications
Safety and efficacy not established in pregnant women. Use with caution in pregnancy or lactation.
Unlabeled use
Contraindications
Hypersensitivity to amide-type anesthetics. Ophthalmic use.
Warnings and precautions
Rectal and topical formulations of dibucaine contain acetone sodium bisulfite (possible risk of anaphylaxis and life-threatening or less severe asthmatic episodes in susceptible individuals). Risk of serious adverse effects (e.g. seizures, coma, irregular heart beat, respiratory depression) with use of topical local anesthetics.